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Abstract: Significant advances in the treatment of rheumatoid arthritis (RA) have been made 
over the past 10 years with the introduction of biologic therapies, such as the TNF inhibitors. 
With these medications, many patients with RA have seen significant improvement in symptoms, 
function, and quality of life. However, with the introduction of the biologics, decision-making 
for this chronic disease that affects up to 1% of the population has become even more complex. 
Patient preferences for mode and frequency of administration, and for certain risks vs benefits 
as well as medication beliefs are central to uptake and adherence to these medications. This 
review examines the current literature on patient satisfaction, adherence, and preference for 
biologic therapy in RA.
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Introduction
Rheumatoid arthritis (RA) affects approximately 0.5% to 1% of the population and 
causes significant morbidity and early mortality.1,2 The introduction of biologic therapies 
over the past 10 years has lead to significant improvement in outcomes for patients 
with RA, including clinical symptoms, quality of life, and function.3 While these newer 
therapies have been shown to be equally efficacious when compared to traditional 
disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate,4–9 they 
present different choices for route of administration, increased or different toxicities, and 
higher financial costs, all of which may impact patient preference and adherence.
Assessing patient preferences for treatment in RA is a necessary step toward 
improving outcomes by ensuring satisfaction and adherence. Health disparities in 
outcomes and utilization in RA have been reported by race/ethnicity, education level, 
and insurance status.10–14 Another possible proposed mechanism for these disparities 
is differences in patient preferences.15 In 2003, the Institute of Medicine published 
a report entitled Unequal Treatment: Confronting Racial and Ethnic Disparities in 
Health Care which defined patient preferences as “choices regarding healthcare 
that are based on a full and accurate understanding of treatment options”.16 In any 
assessment of patient preference, it is essential that patients have been fully informed 
of risks and benefits for a particular treatment. Another important factor for effec-
tive, informed decision-making is trust in the physician, since trust has been shown 
to have a greater effect on the patient’s confidence in a DMARD decision than his 
or her DMARD-specific knowledge, disease-related factors or demographics.17 
While knowledge and trust have not been extensively examined in the context of Patient Preference and Adherence 2009:3 336
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studying patient preferences for treatment in RA, it is 
important to keep sight of these concepts when reviewing 
the literature.
The objectives of this review are to examine the current 
literature on patient preferences, satisfaction, and adherence 
to the biologic DMARDs (limited to the TNF inhibitors) for 
RA treatment.
Overview of treatment of RA
The main treatment goals for RA include control over pain 
and inflammation, halting progression of bony erosions, 
and improving function.4 Therapy for RA has undergone 
significant evolution since the introduction of biologic 
therapies in 1998. The course of the disease can vary from 
person to person, and can also vary in intensity within each 
patient which requires tailored, individualized therapy. Both 
traditional (or non-biologic DMARDs such as methotrexate) 
as well as the biologic DMARDs require frequent monitoring 
for toxicity as well as clinical response, necessitating frequent 
visits with a rheumatologist. Given the spectrum of disease 
activity and manifestations across individuals as well as 
the ever growing armamentarium of RA medications, there 
exists no standardized algorithm for treatment. As a guide 
for clinicians, the American College of Rheumatology (ACR) 
published recommendations in 2008 for the initiation of 
non-biologic and biologic DMARDs for the treatment of 
RA using various algorithms based on duration of disease, 
presence of poor prognostic factors (eg, rheumatoid factor 
positive, presence of erosions on X-ray) and level of disease 
activity.18 The mode of delivery for the biologic DMARDs 
(intravenous or subcutaneous injection) and the frequency of 
administration varies, introducing additional variables and 
choices for patients (Table 1).
Because treatment options, toxicities and mode of 
delivery vary, it is essential that patterns of adherence, 
patient preference and satisfaction for therapy in RA are 
examined.
Patient satisfaction  
with medications in RA
The following section summarizes 6 studies which report on 
some aspect of satisfaction or expectation of therapy in RA. 
Given that no standard, routinely used measure of satisfaction 
exists in the rheumatology literature, no set criteria for 
defining satisfaction was applied to the studies below. The 
methods for ascertaining satisfaction across studies was not 
uniform, and ranged from qualitative methods in 2 studies 
(using focus groups)19,20 to the use of questionnaires in the 
Table 1 Biologic DMArDS – route of administration, dose, cost and year introduced
Drug name Brand name Dose2 Frequency Price per month3 Year1
Non-biologic DMARDs – oral Generic Brand
Methotrexate rheumatrex 7.5 mg once weekly $40 $45 1988
Trexall 15 mg once weekly $80 $90
20 mg once weekly $105 $120
Biologic DMARDs – subcutaneous
Adalimumab Humira 40 mg every 2 weeks NA $1,585 2002
Anakinra Kineret 100 mg daily NA $1,445 2001
etanercept enbrel 25 mg twice weekly NA $1,585 1998
50 mg once weekly NA $1,585
Biologic DMARDs – intravenous
Abatacept Orencia 500 mg every 4 weeks NA $1,080 2005
750 mg every 4 weeks NA $1,620
1000 mg every 4 weeks NA $2,160
Infliximab remicade 3 mg/kg every 8 weeks NA $730 1999
6 mg/kg every 8 weeks NA $1,465
10 mg/kg every 8 weeks NA $2,440
rituximab rituxan 1000 mg 2 weeks apart, 2 doses NA $1,015 2006
Notes: 1indicated year FDA approved for use in rheumatoid arthritis; Sources: www.fda.gov if not otherwise cited.
2Doses representative of those used in research studies or typical for rA. 
3Average wholesale Price (US$) from Drug Topics red Book, 2007. Price does not include infusion-related expenses.
Abbreviations: DMArDs, disease-modifying antirheumatic drugs; NA, not available as generic.
Adapted from Rheumatoid Arthritis Medicines: A Guide for Adults. AHrQ Pub. No. 08-eHC004-2A.   April 2008.   Agency for Healthcare research and Quality.  rockville, MD.49 Used 
with permission. http://effectivehealthcare.ahrq.govPatient Preference and Adherence 2009:3 337
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remaining 4 studies.21–24 Only one paper reported a rigorous 
method for developing questions about satisfaction with 
treatment.21 Carbonell and Badia described an initial literature 
search, compilation of questions, review by four experts 
for comprehension and applicability, followed by a second 
version of the questions which were then piloted in 14 patients 
and refined into the final questionnaire.21
Kjeken et al used both closed and open-ended questions in 
their study of over 1000 Norwegian RA patients’ satisfaction 
with care and found that 68% were very or somewhat satisfied 
with the health care they received while only 8% were 
somewhat or very dissatisfied.22 They also noted that those 
patients who had a high level of involvement in their care 
were more likely to be satisfied (91% satisfied in the high 
involvement group vs 61% satisfied in the low involvement 
group).22 In terms of identifying predictors of unmet 
expectations among patients with rheumatic diseases, Rao 
and colleagues performed a longitudinal study of 177 subjects 
(39% with RA) in the US using a series of 6 questions.23 
They found that 33% of patients reported at least one unmet 
expectation after a clinic visit with the most common reasons 
being unfulfilled expectations for information (47%), 
medication changes (31%) and physician examination (29%). 
Among those patients with unmet expectations, they were 
more likely to report poorer functional and psychological 
status at baseline, higher levels of learned helplessness, 
more pain and shorter physician visits in unadjusted analysis. 
Followed longitudinally, those reporting unmet expectations 
had an increase in pain score whereas those who did not had 
a slight decrease in pain (P = 0.002).23
With regard to satisfaction with therapy, Wolfe and 
Michaud conducted a large, cross-sectional survey of more 
than 6000 subjects with RA in the US to explore patients’ 
acceptance and satisfaction with their current therapy (both 
biologic and non-biologic DMARDs), willingness to alter and 
reasons for not changing therapy.24 Subjects were enrollees 
of a longitudinal cohort and no additional education on 
specifics of alternative therapy was provided as part of this 
study. Overall, 77.3% of subjects were very satisfied or some-
what satisfied with their medications. Nearly three quarters 
of the patients reported not wanting to risk side effects of 
new medications, and 35.7% did not want to take treatments 
which required injections or ivs (the biologic DMARDs). 
The authors found very weak associations between measures 
of function, RA severity, and degree of satisfaction with 
control of their RA. They note that most RA patients in 
this study were satisfied with their current therapy despite 
many patients with abnormal scores on function and disease 
activity. However, they did report a small, but statistically 
significant difference in satisfaction among current biologic 
DMARD users and non-biologic users with the non-biologic 
users slightly more satisfied with their current treatment. 
In examining potential predictors of unwillingness to change 
therapy in this cohort, belief that RA control was adequate 
(odds ratio [OR] = 6.8) and fear of side effects (OR = 4.4) 
were the top predictors, adjusting for sociodemographic and 
RA factors.24
In a qualitative study done in the UK in 2004, Marshall 
and colleagues specifically asked a small group of RA 
patients (n = 19) about their experiences and views of 
2 TNF inhibitor therapies (infliximab and etanercept).19 The 
median RA disease duration of this group was 11 years, 
but average length of time on the TNF inhibitors was not 
reported. Patients expectations of treatment varied from low 
(“Not really expecting anything”) to desperation (“literally 
to go for anything that’s available”) to higher expectations 
(“I’m going to be cured with in a couple of months”). The 
experience with these two biologic DMARDs was overall 
very positive: “marvelous”, “thrilled to bits”, “it’s like being 
a normal person.” The negative experiences related to lack of 
effect or side effects, yet there was little concern about the 
medications being a newer class of drug. Patients were aware 
of the high cost of the drugs and reported anxiety over the 
process of qualifying for the medication in the UK.19
A 2008 prospective study in Spain conducted on 
198 subjects initiating therapy with infliximab assessed 
patient expectations with regard to treatment efficacy through 
a series of questions at multiple time points, including at 
baseline, 2, 6 and 14 weeks. After 2 weeks, 90% of patients 
reported that their expectations for treatment had been met 
and for 50%, expectations were surpassed. Patients satisfied 
with treatment was 19.4%, 76.9% and 85.5% at baseline, 
2 weeks and 14 weeks respectively.21
An example of patients’ views differing from those of 
their rheumatologists is found in a 2008 qualitative study 
by van Tuyl et al in the Netherlands.20 While not directly 
assessing perspectives on biologic therapy, the objective of 
this study was to investigate opinions and beliefs of both 
physicians and patients in regard to COBRA (combination 
therapy in early rheumatoid arthritis) therapy through focus 
groups and in-depth interviews. COBRA consists of a step-
down combination therapy of methotrexate, sulfasalazine 
and high dose prednisolone which is tapered over 6 weeks 
from 60 mg to 7.5 mg daily. The striking finding in this 
study is how discordant physicians’ views were from the 
patients. Physicians perceived potential practical problems Patient Preference and Adherence 2009:3 338
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with the therapy as well as negative emotions from patients 
and therefore were reluctant to prescribe the combination. 
One physician stated: “The patient leaves the room and says: 
‘this doctor is completely nuts. I enter with pain in my wrist 
and I leave with 8 different kinds of tablets!’ ”. Patients 
were much more positive: “I started with methotrexate, four 
tablets, well it gradually became more, and I thought ‘give 
me as much as possible’, because I really revived.” Patients’ 
expectations of treatment were fairly uniform: less pain, 
improved function and quality of life. They also held trust 
in physician as being very important.20
In summary, patient satisfaction with their current RA 
treatment was quite high and willingness to change therapy 
to better control disease activity or improve function was 
curtailed by fear of side effects. With regard to biologics, 
specifically, patient expectations were variable, with some 
patients placing very high expectations on these therapies.
Adherence and biologic  
therapies in RA
Treatment adherence in arthritis has been reported to be 
between 30% and 78%.25 While the descriptive terms of 
medication-taking present challenges in that they can 
sometimes be viewed as paternalistic,26 this review will 
use the terms “adherence,” meaning the patient takes a 
medication according to the prescription, and “medication 
persistence,” time from initiation to discontinuation of the 
treatment.27 In addition to variations on the definitions of 
terms, the methods for measuring adherence and persistence 
also vary but will not be debated in this review. First, the 
Table 2 Treatment adherence/survival for biologic DMArDs in rheumatoid arthritis
Author Year, Country Medication Study 
size (n = )
Adherence  
evaluation
Adherence or 
survival (%)a
Flendrie31 2003, Netherlands Adalimumab 94 electronic registry 73
Infliximab 83 66
etanercept 14 74
Chung30 2003, Canada Infliximab 163 chart review 70.8
Harley28 2003, USA Infliximab 141 claims data 80.9b
etanercept 853 68.4b
wendling29 2005, France Infliximab 41 physician assessment 74
Zink32 2005, Germany Infliximab 343 physician assessment 65.4
etanercept 511 68.6
Anakinra 70 59
Kristensen33 2006, Sweden Infliximab 50 physician assessment 47
etanercept 128 74
Infliximab + MTX 339 69
etanercept + MTX 100 89
Grijalva27 2007, USA Infliximab 75 claims data 85c
Adalimumab 120 134c
etanercept 374 175c
Anakinra 72 156c
Infliximab + MTX 98 155c
Adalimumab + MTX 107 219c
etanercept + MTX 262 147c
Hetland48 2008, Denmark All biologics
2000/2001 Inflix/eta/ada/other 87/13/0/0 73
2002 Inflix/eta/ada/other 95/2/3/0 62
2003 Inflix/eta/ada/other 49/23/25/3 67
2004 Inflix/eta/ada/other 36/31/33/0 70
2005 Inflix/eta/ada/other 34/18/46/2 69
Notes: aAt 12 months unless otherwise specified; bCompliance with 80% expected doses; cThis number reflects the median persistence of the medication in days.
Abbreviations: MTX, methotrexate; inflix, infliximab; eta, etanercept; ada, adalimumab.Patient Preference and Adherence 2009:3 339
Patient preferences for biologic therapy in rA Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
data on adherence and persistence will be summarized 
(Table 2), and then predictors of treatment adherence will 
be explored.
Harley and colleagues evaluated claims data on 2662 
RA patients residing in the US with the objective of 
examining treatment adherence with 2 TNF inhibitors, 
infliximab (administered intravenously) and etanercept 
(self-administered subcutaneously) between July 1998 and 
December 2000.28 Of the 141 subjects on infliximab, 80.9% 
had compliance with at least 80% of the expected doses 
compared with 68.4% of the 853 subjects on etanercept. They 
also examined adherence to oral methotrexate and found 
that 63.7% of the 1668 subjects were adherent with at least 
80% of expected doses. They did not examine predictors 
of adherence and it should also be noted that Centocor, the 
manufacturer of Remicade® (infliximab), was involved in 
the preparation of the manuscript and may have biased the 
results toward infliximab.28
The timing of the availability of TNF inhibitors varied 
between Europe and the US with etanercept being the first 
available in the US and infliximab was the first available in 
France. A study by Wendling et al examined continuation 
rates of infliximab in France from March 2000 through June 
2003.29 Forty-one patients were followed for a minimum of 
6 months. Treatment continuation rates were as follows: 
82% at 6 months, 74% at 12 months, 67% at 24 months 
and 20% at 36 months. Throughout this study period, 
14 (34%) discontinued treatment (reasons included escape 
phenomenon, allergy, ineffectiveness, poor compliance, 
infection, and pregnancy).29 The continuation rates at 
12 and 24 months for infliximab in this study mirror those 
of other studies done in Canada (70.8% and 63.4% at 12 and 
24 months, respectively),30 France (70% at 24 months), and 
the Netherlands (66% at 12 months).29,31
A 2005 prospective study in Germany by Zink and 
colleagues examined the drug continuation rates after 
12 months in 511 subjects on etanercept (68.6%), 343 on 
infliximab (65.4%) and 70 on anakinra (59%) compared 
to 599 subjects on non-biologic DMARDs.32 Treatment 
continuation was more likely for those who were on 
combinations of a biologic and a non-biologic DMARD. 
Predictors of premature termination of therapy with a biologic 
were number of prior DMARDs (hazard ratio [HR] = 1.09, 
95% confidence interval [CI] 1.10 to 1.18), rheumatoid factor 
(HR = 1.53, 95% CI 1.09 to 2.16) and greater age (HR = 1.01, 
95% CI 1.00 to 1.02).32 Another study performed in Sweden 
confirmed that concomitant use of a non-biologic DMARD 
(such as methotrexate) with biologic therapy can protect 
against premature termination with a biologic perhaps due 
to improved efficacy.33 Kristensen and colleagues performed 
a prospective study between 1999 and 2004 on 1161 biologic 
naïve patients to investigate predictors associated with 
premature TNF inhibitor treatment termination. They 
reported data at 1, 4 and 5 years. In comparison to prior studies 
cited in this review, only the 1-year data are presented here. 
Adherence at 1 year is as follows: combination of infliximab 
plus methotrexate: 69%; etanercept plus methotrexate: 89%; 
infliximab monotherapy: 47%; etanercept monotherapy: 74%. 
Other predictors of premature treatment termination in this 
study included low c-reactive protein level, older age, greater 
disability, and higher previous number of DMARDs.33
In summary, compared to prior ranges of adherence to 
medication in RA (including non-biologic DMARDs),25 
adherence to the TNF inhibitors is fairly high. In addition, 
studies show that combinations of non-biologic and biologic 
DMARDs demonstrated the highest rates of adherence.
Medication beliefs and predictors  
of treatment adherence in RA
Several studies have more closely examined factors which 
may predict adherence to treatment in RA, from the financial 
cost to sociodemographic and psychological characteristics, 
including beliefs about medication. Patient beliefs related to 
the necessity of medication have been shown to be associated 
with adherence34 and medication beliefs among subjects 
with RA have been shown to vary among different ethnic 
groups.25,35
Treharne and colleagues aimed to investigate the effects 
of psychosocial factors on adherence to medication in 85 RA 
patients in an outpatient setting in England.36 The mean age 
was 59 with mean disease duration of 10 years. The most 
commonly prescribed DMARD was methotrexate (58%), 
and no details on biologic therapy were reported. Overall 
adherence to medication in this study was quite high with 
94.2% and 90.6% responding “never” or “rarely” to how 
often participants forgot to take their medication and how 
often they miss out or adjust a dose of medication. In a 
hierarchical regression model, total number of medications, 
perceptions of specific necessity of their medications 
and their (lack of) beliefs about the general overuse of 
medications explained up to 64% of the variance in adher-
ence with rheumatology medications.36 This study reinforces 
the importance of understanding patients’ attitudes toward 
treatment, and involving them in shared decision making to 
ultimately improve adherence. While not directly assessing 
beliefs about biologic therapies in RA, one could extrapolate Patient Preference and Adherence 2009:3 340
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these results to all medications used to treat this chronic, 
debilitating disease.
Another cross-sectional study from the UK evaluated 
344 RA patients in the form of a questionnaire with regard 
to medication beliefs.34 Neame and Hammond report that 
most (74.3%) of the respondents agreed or strongly agreed 
that their RA medications were necessary for their health 
(93% of patients reported taking a DMARD). However, 
almost half (47.4%) expressed concern over potential 
adverse consequences. The authors used an adaptation of 
the Beliefs about Medicines Questionnaire (BMQ) which 
consists of two five item scales which capture the two core 
beliefs held by patients: 1) the necessity for medications 
to maintain health (necessity score) and 2) concerns about 
the potential side effects of taking medications (concern 
score).34,36 They found that greater levels of pain, fatigue, 
and physical disability were associated with greater belief 
in the necessity of medications as well as greater concerns. 
In terms of the relationship between adherence and beliefs, 
the necessity scores for the adherent were not significantly 
different than the non-adherent. However, there was a dif-
ference in concern scores between the two groups with the 
mean score for the adherent group being significantly lower 
than for the non-adherent (P = 0.002).34
A US-based study examined adherence and predictors 
of adherence in an underserved, ethnically diverse cohort 
of 102 RA and lupus patients.25 As a group, nearly 80% 
reported that they “never” or “rarely” forgot to take medi-
cations; however upon comparing ethnic groups, African 
American patients had a lower adherence score than Whites 
and were more likely than Whites to discontinue medica-
tions on their own because they felt they were “not helping.” 
In terms of the reasons why subjects missed or discontinued 
therapy, the most common reasons were running out of pills 
(37%), forgetting (30%), feeling depressed (27%), being 
away from the home (27%), and feeling well (25%). African 
Americans and Hispanics were more likely than Whites 
to stop a medication because they felt it was harmful or 
toxic.25 The other differences between Whites and ethnic 
minorities were also found in the following reasons for miss-
ing medications: 1) asleep at dose time; 2) felt sick or ill; 
3) depressed/overwhelmed; or 4) difficulties with scheduled 
times. One other study that explored ethnic differences in 
medication beliefs in RA and lupus was conducted in out-
patient settings in the UK with equal numbers of patients 
of South Asian origin (3 or more grandparents born in India 
or Pakistan) and those of White British/Irish origin.35 This 
study found that patients of South Asian origin believed 
that medications in general were more overused and more 
harmful compared to patients of White British/Irish origin. 
The patients of South Asian origin also expressed more 
concern over DMARDs.35
Given the significant difference in cost between the 
biologic DMARDs as compared to the non-biologic 
DMARDs (Table 1), one must consider the impact of cost 
on adherence. Curkendall and colleagues studied the impact 
of patient out-of-pocket (OOP) expenditures on adherence 
and persistence with the biologic DMARDs using claims 
data from 2285 insured RA patients starting either etan-
ercept or adalimumab during 2002–2004.37 Seventy-five 
percent of subjects started etanercept compared to 25% 
initiating therapy with adalimumab. The mean OOP cost 
per week was US$7.84 ± US$14.15 and 92% of patients 
had OOP costs less than US$20 per week. In unadjusted 
and adjusted analyses, higher OOP costs were associated 
with lower levels of adherence. Other variables associ-
ated with lower adherence in adjusted analysis were female 
gender and HMO insurance. Use of DMARDs prior to TNF 
inhibitor therapy and residence in the north-eastern US 
were both associated with higher adherence. With respect 
to persistence, patients with OOP costs greater than US$50/
week were 58% more likely to stop therapy than those with 
lower OOP costs.37
In summary, subjects with prior DMARD use, strong 
beliefs in the necessity of medication for their health, and 
lower out of pocket costs had higher rates of adherence to 
RA medications, specifically biologic therapy.34,36,37 Concern 
for toxicity of medication was associated with lower rates of 
adherence, especially among ethnic minorities.25,38
Patient preference for biologic 
therapies in RA
The first two studies to examine patient preference for 
biologic therapies in RA were published in 2004. A meeting 
abstract from the European Union League Against 
Rheumatism described results from face to face interviews 
with 300 subjects from the European Union (EU) and 174 
from the US. The objective of this study was to determine 
preferences for administration methods. Less than 25% of 
the EU and 18% of US subjects preferred intravenous over 
subcutaneous administration and over three-fourths of all 
patients preferred a “ready to use” prefilled syringe when 
compared to products requiring reconstitution or admin-
istration via iv every 8 weeks in hospital.39 In a separate 
study, Fraenkel and colleagues employed a method known 
as Adaptive Conjoint Analysis (ACA) to examine patient Patient Preference and Adherence 2009:3 341
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trade-offs between specific drug characteristics and identify 
individual patient preferences for specific DMARDs.40 The 
authors assessed the individual characteristics of treatment 
options by the value given it by the patient. Patients were 
then given a scenario, the “base case,” which presented 
several treatment options using the maximum benefit of 
a medication taken from those benefits reported in the 
literature, a low probability of adverse effects and low equal 
monthly co-pays. For this base case, 95% of subjects pre-
ferred an option similar to etanercept over the other options. 
When they altered the scenario characterizing etanercept as 
being associated with rare (0.1%) but serious infection risk, 
the number of patients selecting TNF inhibitors fell from 
95% to 79%.40
While the efficacy of the three TNF inhibitors has not 
been rigorously evaluated in head to head trials comparing 
all 3 drugs, the route of administration and frequency differs 
and plays a role in decision-making for patients with RA. 
Williams and Edwards communicated the results of their 
study on patient preferences for TNF inhibitors in a 2006 
letter to the editor.41 Of the 100 consecutive patients seen in 
an outpatient clinic during 2004, 50 were on a TNF inhibitor 
while the remaining 50 were on a conventional DMARD 
(10 subjects were then excluded due to lack of response 
on the questionnaire). Subcutaneous administration was 
preferred in both groups (41% of those on anti-TNF; 52.5% 
not). The majority of subjects also preferred administration 
at home (62.5% on anti-TNF; 52% not). The authors did note 
that of those patients on anti-TNF therapy, their preferences 
corresponded with the route and frequency of administration 
of the drug they were currently taking, suggesting they were 
satisfied with their treatment.41
Among subjects with early RA (2 years), Goekoop-
Ruiterman and colleagues investigated patient preferences 
for their initial therapy in a randomized-controlled trial 
comparing 4 different treatment options conducted in the 
Netherlands (the BeST trial).42 The four treatment arms 
were as follows: 1) sequential monotherapy, beginning 
with methotrexate; 2) step-up combination therapy, starting 
with methotrexate; 3) initial combination therapy with 
methotrexate, sulfasalazine and prednisone; and 4) initial 
combination therapy with methotrexate and infliximab. 
It should be noted that after 2 years in the trial there were no 
significant differences in functional and clinical outcomes 
among the four groups, however those in the groups with 
initial combination therapy either with prednisone or 
infliximab had a more rapid improvement of function, 
and clinical signs and symptoms than the other groups. 
Four hundred and forty out of 508 participants responded 
to the questionnaire on preferences. In terms of satisfaction, 
patients in group 4 (methotrexate and infliximab) stated their 
health improved much to very much since starting therapy 
(50%, 56%, 47%, and 74% in groups 1 to 4, respectively), 
and those in group 3 were the least satisfied (85%, 88%, 
72% and 85% respectively). Pretrial preference was highest 
for group 4 with 62% in group 4, and 22% in groups 1, 2, 
and 3 stating that treatment would have been their prefer-
ence. Subjects were then asked if they were diagnosed with 
RA today, what treatment would they prefer: 21% would 
choose a treatment with a well-known antirheumatic drug, 
19% would choose a combination without prednisone, 12% 
would choose a combination with prednisone, and 44% 
would chose a combination with the “newest” intravenous 
drug (infliximab).42
Chilton and Collett undertook a mixed methods approach 
to exploring preferences for TNF inhibitor therapy among RA 
patients in the UK.43 They sent questionnaires to 200 subjects 
on combination or triple therapy with non-biologic DMARDs 
and also conducted one on one interviews with 7 patients 
who had changed from one TNF inhibitor to another. The 
response rate for the questionnaire was 56%. In addition 
to querying patients on their preferences for treatment, 
they also asked about patients’ views on who should make 
decisions regarding therapy. A total of 45 (41%) responded 
that the rheumatologist should decide, 7% preferred a joint 
decision, 33% wanted to make the decision themselves, and 
19% were undecided. This demonstrates how widely patient 
preference for decision-making can vary. In terms of mode 
of administration of drug, almost half preferred to administer 
their own treatment (self-inject) vs a third who would not, 
and 22% were unsure. Younger patients were significantly 
more confident about self-administering treatment. 
Adalimumab was the most preferred of the TNF inhibitors 
by both the questionnaire respondents (47% compared to 
23% for infliximab and 4% for etanercept, 27% no prefer-
ence) and for all of those interviewed. The interviewees 
preferred adalimumab because of the convenience of self-
administration and how it “would allow them to regain control 
of their lives.” In addition to convenience, other factors which 
contributed to this treatment preference were not needing to 
prepare the medicine, reduced change of medication error, 
use of ready-to-use syringe with correct dose and not needing 
to travel to the hospital. However, among those who did 
choose infliximab (administered iv), “contact with patients/
meeting others” as well as “staff available if problems arose” 
were both significant factors influencing their choice.43Patient Preference and Adherence 2009:3 342
Barton Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Constantinescu and colleagues explored whether or not 
treatment preferences in RA varied by race.44 Using the 
technique of adaptive conjoint analysis described earlier in 
this review,40 the authors studied 136 consecutive patients 
with RA (67 African American, 69 White). In unadjusted 
analysis, 51% of Whites vs 16% of African Americans 
preferred a more aggressive therapy (P  0.0001). Married 
subjects and those who reported at least some college 
education had stronger preferences for aggressive therapy 
compared to those who were not married or had no college 
education. After adjustment for other covariates, race 
remained the strongest predictor of aggressive therapy 
(adjusted odds ratio = 11.2, 95% CI 1.9 to 64.9). In another 
paper based on this study population, the same authors sought 
to determine how these two racial groups viewed risks and 
benefits related to medication as a possible explanation for 
the divergent preferences.45 They calculated values for the 
“relative importance” of each characteristic and noted that 
African Americans and Whites differed significantly in which 
particular treatment characteristics they viewed as having 
more relative importance than others. For instance, African 
Americans were most influenced by the theoretical risk of 
cancer (over other risks as well as treatment benefits) while 
Whites were most influenced by the likelihood of remission 
or likelihood of halting radiographic progression of disease. 
They also looked at risk aversion and found that 52% of 
African Americans were risk averse compared with 12% of 
Whites (P  0.0001).45
In summary, patients prefer subcutaneous over iv 
administration of the TNF inhibitors and prefer to receive 
treatment at home.39,41,43 When given a choice among various 
options for therapy, including non-biologic or biologic 
DMARDs, patients chose a biologic or a combination therapy 
which included a biologic.40,42 The one study which explored 
racial differences found that African Americans preferred 
less aggressive therapy when compared with Whites and that 
they placed higher importance on risk over benefit when 
compared to Whites.44,45
In conclusion, treatment options for patients with RA 
continue to expand, creating opportunity for improved out-
comes such as decreased pain, less disability and decreased 
mortality. However, with the introduction of newer therapies, 
patients as well as physicians are faced with increasingly 
complex decisions about how, when, and at what cost (both 
financially and with regard to toxicity) a medication will 
be initiated and continued. Patient preferences for TNF 
inhibitors need to be explored in more depth in populations 
at higher risk for poor communication with their physicians 
(those with low literacy, lower levels of education and 
immigrants) and at risk for incomplete understanding or 
misunderstanding of the risks and benefits of these potentially 
transforming medications.
Patients with RA prefer that education about the disease 
and its treatment be delivered on a one-to-one basis from 
health professionals.46 Patient preference and medication 
beliefs are associated with adherence47 and to ensure the best 
possible outcome for our patients with this destructive and 
debilitating disease, we must first provide comprehensive 
education regarding RA and its treatment options, elicit 
preferences, concerns about medications, and ensure that 
all patients possess an accurate and clear understanding of 
treatment risks and benefits to fully inform their decision 
making. A randomized, controlled trial of an educational 
and decision-making tool specifically designed for biologic 
DMARDs in an ethnically diverse population of adults 
with RA will help us discover the most effective way to 
communicate the complexities of these medications and 
also elicit preferences to allow for the maximum benefit for 
all patients.
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